

People

Appointments

Cellomics announces new CEO

Dan Calvo has been appointed by Cellomics (<http://www.cellomics.com>) as Chief Executive Officer, succeeding D. Lansing Taylor, who will remain as Chairman of the Board of Directors. Calvo joins Cellomics from Perkin Elmer Life Sciences, where he was Vice President of Worldwide Sales and Service. Before this, he was Senior Vice President, Global Sales and Marketing for NEN Life Sciences, following a 15-year career at DuPont in various sales and marketing positions.

On his appointment, Calvo commented: 'I am pleased to join Cellomics and lead the ongoing development and full commercialization of our integrated solution in the field of 'cellomics' and in the markets of High Content Screening that the company pioneered.' D. Lansing Taylor added: 'The Board of Directors is extremely pleased to have recruited Dan as the next CEO of Cellomics. His skills, experience and leadership capabilities will develop a stronger operational and commercial focus aimed at improving our market penetration and financial performance.'

Promotions at AtheroGenics

AtheroGenics, a pharmaceutical company dedicated to researching treatments for chronic inflammatory diseases (<http://www.atherogenics.com>) has announced three promotions.

Charles Kunsch was promoted from Director of Biological Research to Senior Director of Biological Research. Kunsch has been with AtheroGenics since 1997, before which he was a research scientist at the Dept of Exploratory Research at Human Genome Sciences. His new role will include responsibility for implementing and overseeing early discovery technology to identify and validate new anti-inflammatory drug targets, coordinating biomolecular screening activities, and biological characterization of lead molecules.

In a second promotion, James A. Sikorski has taken on the role of Senior Director of Discovery Medicinal Chemistry (previously

Director), and now oversees all new discovery chemistry efforts supporting AtheroGenics v-protectant™ and kinase technology platforms. Sikorski has 25 years experience in chemical research, and was previously a Science Fellow in Medicinal Chemistry for Pharmacia and Searle working on several cardiovascular and anti-inflammatory programs.

AtheroGenics also announce the promotion of Cynthia L. Sundell from Associate Director of Pharmacology to Director of Pharmacology. Sundell has served with the company since 1995, and was formerly a Senior Research Associate in the Dept of Medicine at Emory University School of Medicine. Her new role will oversee the pharmacological characterization of lead compounds arising from discovery research, as well as developing and implementing *in vivo* models of disease in atherosclerosis, rheumatoid arthritis and asthma.

New Director at TAP

The Automation Partnership (TAP; <http://www.automationpartnership.com>) has recently announced the appointment of Tim Ward as Director of the Cell Culture Group. Ward has more than 20 years experience in the automated solutions industry and in his new role will be responsible for coordinating all activities and development initiatives of TAP's cell culture business. Richard Archer, CEO of TAP, commented that: 'Tim is a terrific addition to TAP and I'm delighted that he has joined our team. His extensive experience and background in laboratory automation and life sciences will be a valuable asset.' Ward previously worked with Beckman Coulter for more than 17 years, most recently as Marketing Manager – Automated Solutions Europe. On his appointment with TAP, he commented: 'I am very pleased to be joining TAP. I look forward to facing a new set of challenges, responsibilities and working in this most exciting field of cells and cell culture.'

Former Pharmacia executive heads PediaMed

Cameron Durrant has been appointed as President of PediaMed Pharmaceuticals

(<http://www.pediamedpharma.com>), a company that identifies, develops and markets prescription and OTC drugs specifically to treat children. 'PediaMed is in an excellent position to seize the opportunities afforded by the growing pediatric pharmaceutical market', says Durrant, 'I am looking forward to helping further "raise the bar" in terms of sales, customer service and business and corporate development activities.'

Durrant formerly served as vice president and head of global business planning and operations at Pharmacia, where he led the global antibiotic marketing team. Before this, he held senior sales and marketing positions with GlaxoWellcome and Merck and Co. in the UK. He has also practiced as a physician and been involved in several entrepreneurial businesses in the US, UK and Australia. Roger Griggs, Chairman of the Board of Directors for PediaMed said: 'We are very pleased to have been able to attract an outstanding pharma leader with proven medical and marketing know-how.'

German researcher wins award in mass spectrometry

Wolf Lehmann, a Professor at the German Cancer Research Center in Heidelberg, Germany, has won the Applied Biosystems award for excellence in mass spectrometry (MS) in the life sciences. The award and prize of 5000 Euros recognizes individuals who have extensively contributed to the development and application of MS to life sciences, and was awarded to Lehmann in recognition of his achievements working on the analysis of polar lipids using mass spectrometry. Lehmann has published numerous articles on this, and other applications of MS to proteomics, and wrote the frequently referenced book *Massenspektrometrie in der Biochemie*, which was published in 1996.

Commenting on his work, Lehmann said: 'I really like the work we do here – it's a mixture of methodological improvement and more or less direct application. Our work is driven by the problems colleagues experience, and I find it personally very satisfying.'

People was written by
Joanna Owens